NCT03360006 - A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 16, 2018

Primary Completion Date

December 19, 2020

Study Completion Date

December 19, 2020

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG

ABBV-744

Tablet, oral

Trial Locations (7)

Cleveland Clinic Main Campus /ID# 160756, Cleveland

Northwestern /ID# 171098, Chicago

University of Texas MD Anderson Cancer Center /ID# 160701, Houston

UC Irvine /ID# 160789, Orange

University of California, Davis Comprehensive Cancer Center /ID# 202729, Sacramento

Swedish-Center for Blood Disor /ID# 166487, Seattle

University of Chicago DCAM /ID# 160702, Chicago